Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hantech Bio-Technology CoROCO:1294 -2.32%73 Return-on-Tangible-Equity is 20.18% as of Mar. 2026, which is 7% below its 10-year median of 21.64. GuruFocus rates ROCO:1294 with a GF Score™ of 73/100 and a GF Value™ of NT$77.48 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,880 Consumer Packaged Goods companies, Hantech Bio-Technology Co ranks better than 75.11% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Hantech Bio-Technology Co's annualized net income for the quarter that ended in Mar. 2026 was NT$170.9 Mil. Hantech Bio-Technology Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was NT$846.9 Mil. Therefore, Hantech Bio-Technology Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 20.18%.
The historical rank and industry rank for Hantech Bio-Technology Co's Return-on-Tangible-Equity or its related term are showing as below:
ROCO:1294'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 9.63 Med: 21.64 Max: 49.64
Current: 17.23
During the past 7 years, Hantech Bio-Technology Co's highest Return-on-Tangible-Equity was 49.64%. The lowest was 9.63%. And the median was 21.64%.
ROCO:1294's Return-on-Tangible-Equity is ranked better than 75.11% of 1880
companies
in the Consumer Packaged Goods industry
Industry Median: 7.87
vs ROCO:1294: 17.23
Hantech Bio-Technology Co (ROCO:1294) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Hantech Bio-Technology Co Return-on-Tangible-Equity Related Terms
Hantech Bio-Technology Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Hantech Bio-Technology Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hantech Bio-Technology Co Return-on-Tangible-Equity Chart
ROCO:1294 vs KHC, GIS: Return-on-Tangible-Equity Comparison
For the Packaged Foods subindustry, Hantech Bio-Technology Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hantech Bio-Technology Co Return-on-Tangible-Equity vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Hantech Bio-Technology Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Hantech Bio-Technology Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 20.18% mean?
Hantech Bio-Technology Co (ROCO:1294) has a Return-on-Tangible-Equity of 20.18% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Hantech Bio-Technology Co and its competitors. This is near median its historical median of 21.64. Over the past decade, Hantech Bio-Technology Co's Return-on-Tangible-Equity has ranged from 9.63 to 49.64. According to the industry distribution chart, Hantech Bio-Technology Co ranks #468 out of 1880 companies in the Consumer Packaged Goods industry, placing it in the top 24.9%.
Is Hantech Bio-Technology Co's Return-on-Tangible-Equity too high?
Hantech Bio-Technology Co's current Return-on-Tangible-Equity of 20.18% is near median its 10-year median of 21.64. Over the past 10 years, this metric has ranged from a low of 9.63 to a high of 49.64. The Consumer Packaged Goods industry median Return-on-Tangible-Equity is 7.87. Hantech Bio-Technology Co's value of 20.18% is 156.4% above this industry median. Based on the distribution chart, Hantech Bio-Technology Co ranks #468 out of 1880 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Hantech Bio-Technology Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hantech Bio-Technology Co's Return-on-Tangible-Equity compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Hantech Bio-Technology Co ranks #468 out of 1880 companies for Return-on-Tangible-Equity. This places Hantech Bio-Technology Co in the top 25% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.87. Hantech Bio-Technology Co's value of 20.18% is 156.4% above this benchmark. Historically, Hantech Bio-Technology Co's own Return-on-Tangible-Equity has ranged from 9.63 to 49.64 over the past decade. While the company's 10-year median is 21.64 vs. the industry median of 7.87, Hantech Bio-Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Consumer Packaged Goods company?
The median Return-on-Tangible-Equity among Consumer Packaged Goods companies is 7.87, based on 1,880 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hantech Bio-Technology Co's current Return-on-Tangible-Equity of 20.18% is 156.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Hantech Bio-Technology Co and its competitors. For the Consumer Packaged Goods industry, the median Return-on-Tangible-Equity is 7.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hantech Bio-Technology Co's current Return-on-Tangible-Equity is 20.18%, which is near median its own 10-year median of 21.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hantech Bio-Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Hantech Bio-Technology Co (ROCO:1294) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$77.48, compared to a current price of NT$54.80 — trading 29.3% below its estimated fair value. The current Return-on-Tangible-Equity is 20.18%, which is near median its 10-year median of 21.64 and 156.4% above the Consumer Packaged Goods industry median of 7.87. Hantech Bio-Technology Co's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Hantech Bio-Technology Co (ROCO:1294), the current Return-on-Tangible-Equity is 20.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hantech Bio-Technology Co (ROCO:1294) Overvalued in 2026?
Based on GuruFocus' analysis, Hantech Bio-Technology Co stock appears to be undervalued.
The current stock price of NT$54.80 is trading 29.3% below its estimated GF Value™ of NT$77.48.
GuruFocus considers Hantech Bio-Technology Co to be Modestly Undervalued.
Key valuation signals for ROCO:1294:
Return-on-Tangible-Equity: 20.18% (near median its 10-year median of 21.64)
GF Value™: NT$77.48 vs. price of NT$54.80 (29.3% below fair value)
Industry Position: 156.4% above the Consumer Packaged Goods median (#468 of 1880)
No single metric tells the full story. See the ROCO:1294 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hantech Bio-Technology Co Ltd mainly engaged in the manufacture, trading, and agency of biotech foods, health foods, and Traditional Chinese Medicine skincare and beauty products.
73GF Score
Get the complete analysis for ROCO:1294
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1294 has been successfully added to your 
